Literature DB >> 23608244

Categorical and dimensional approaches to negative symptoms of schizophrenia: focus on long-term stability and functional outcome.

Silvana Galderisi1, Paola Bucci2, Armida Mucci2, Brian Kirkpatrick3, Stefano Pini4, Alessandro Rossi5, Antonio Vita6, Mario Maj2.   

Abstract

Negative symptoms of schizophrenia represent a heterogeneous psychopathological domain. Both categorical and dimensional approaches have been proposed to reduce negative symptoms heterogeneity. In the present 5-year follow-up study, long-term stability and impact on outcome of different aspects of negative symptoms were investigated. Following a categorical approach, long-term stability and outcome of deficit schizophrenia (DS), in comparison with nondeficit schizophrenia (NDS), were assessed. Following a dimensional approach, the factor structure and stability of broadly defined negative symptoms and the ability of the identified factors to predict functional outcome were investigated. DS and NDS subjects included in a previous study were invited to participate. Fifty-one out of 58 patients previously diagnosed as DS and 44 out of 54 NDS patients were included in the present study. The DS/NDS categorization was confirmed in 82.4% of DS and 79.6% of NDS subjects. At follow-up, DS patients showed more severe negative symptoms and greater social dysfunction than NDS ones. Schedule for the Deficit Syndrome (SDS) severity scores loaded on two factors: "Poor Emotional Expression" and "Avolition" and the factor structure was stable after 5 years. Avolition was associated to social outcome measures and Poor Emotional Expression to functioning in household activities. Psychosocial outcome was predicted by SDS factors reflecting the severity of broadly defined negative symptoms, but not by the DS/NDS categorization. This might lend support to the recent shift of research focus from the categorical approach focusing on the presence of primary and enduring negative symptoms to the investigation of key domains of broadly defined negative symptoms.
Copyright © 2013 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Year:  2013        PMID: 23608244     DOI: 10.1016/j.schres.2013.03.020

Source DB:  PubMed          Journal:  Schizophr Res        ISSN: 0920-9964            Impact factor:   4.939


  38 in total

1.  Are Negative Symptoms Dimensional or Categorical? Detection and Validation of Deficit Schizophrenia With Taxometric and Latent Variable Mixture Models.

Authors:  Anthony O Ahmed; Gregory P Strauss; Robert W Buchanan; Brian Kirkpatrick; William T Carpenter
Journal:  Schizophr Bull       Date:  2014-11-14       Impact factor: 9.306

2.  The current conceptualization of negative symptoms in schizophrenia.

Authors:  Stephen R Marder; Silvana Galderisi
Journal:  World Psychiatry       Date:  2017-02       Impact factor: 49.548

3.  Progress in the study of negative symptoms.

Authors:  Brian Kirkpatrick
Journal:  Schizophr Bull       Date:  2014-03       Impact factor: 9.306

4.  Assessment of Lifespan Functioning Attainment (ALFA) scale: A quantitative interview for self-reported current and functional decline in schizophrenia.

Authors:  Jamie Joseph; William S Kremen; Stephen J Glatt; Carol E Franz; Sharon D Chandler; Xiaohua Liu; Barbara K Johnson; Ming T Tsuang; Elizabeth W Twamley
Journal:  J Psychiatr Res       Date:  2015-04-11       Impact factor: 4.791

5.  The influence of illness-related variables, personal resources and context-related factors on real-life functioning of people with schizophrenia.

Authors:  Silvana Galderisi; Alessandro Rossi; Paola Rocca; Alessandro Bertolino; Armida Mucci; Paola Bucci; Paola Rucci; Dino Gibertoni; Eugenio Aguglia; Mario Amore; Antonello Bellomo; Massimo Biondi; Roberto Brugnoli; Liliana Dell'Osso; Diana De Ronchi; Gabriella Di Emidio; Massimo Di Giannantonio; Andrea Fagiolini; Carlo Marchesi; Palmiero Monteleone; Lucio Oldani; Federica Pinna; Rita Roncone; Emilio Sacchetti; Paolo Santonastaso; Alberto Siracusano; Antonio Vita; Patrizia Zeppegno; Mario Maj
Journal:  World Psychiatry       Date:  2014-10       Impact factor: 49.548

6.  Convergence and Divergence of Brain Network Dysfunction in Deficit and Non-deficit Schizophrenia.

Authors:  Miao Yu; Zhengjia Dai; Xiaowei Tang; Xiang Wang; Xiaobin Zhang; Weiwei Sha; Shuqiao Yao; Ni Shu; Xindi Wang; Jiaying Yang; Xiangyang Zhang; Xiangrong Zhang; Yong He; Zhijun Zhang
Journal:  Schizophr Bull       Date:  2017-10-21       Impact factor: 9.306

Review 7.  Neurobiological background of negative symptoms.

Authors:  Silvana Galderisi; Eleonora Merlotti; Armida Mucci
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2015-03-24       Impact factor: 5.270

8.  Deconstructing Negative Symptoms in Individuals at Clinical High-Risk for Psychosis: Evidence for Volitional and Diminished Emotionality Subgroups That Predict Clinical Presentation and Functional Outcome.

Authors:  Tina Gupta; Henry R Cowan; Gregory P Strauss; Elaine F Walker; Vijay A Mittal
Journal:  Schizophr Bull       Date:  2021-01-23       Impact factor: 9.306

9.  Interplay Among Psychopathologic Variables, Personal Resources, Context-Related Factors, and Real-life Functioning in Individuals With Schizophrenia: A Network Analysis.

Authors:  Silvana Galderisi; Paola Rucci; Brian Kirkpatrick; Armida Mucci; Dino Gibertoni; Paola Rocca; Alessandro Rossi; Alessandro Bertolino; Gregory P Strauss; Eugenio Aguglia; Antonello Bellomo; Martino Belvederi Murri; Paola Bucci; Bernardo Carpiniello; Anna Comparelli; Alessandro Cuomo; Domenico De Berardis; Liliana Dell'Osso; Fabio Di Fabio; Barbara Gelao; Carlo Marchesi; Palmiero Monteleone; Cristiana Montemagni; Giulia Orsenigo; Francesca Pacitti; Rita Roncone; Paolo Santonastaso; Alberto Siracusano; Annarita Vignapiano; Antonio Vita; Patrizia Zeppegno; Mario Maj
Journal:  JAMA Psychiatry       Date:  2018-04-01       Impact factor: 21.596

10.  Neurocognitive impairment in the deficit subtype of schizophrenia.

Authors:  Gagan Fervaha; Ofer Agid; George Foussias; Ishraq Siddiqui; Hiroyoshi Takeuchi; Gary Remington
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2015-08-11       Impact factor: 5.270

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.